HR Pharmaceuticals, Inc

hrpharma.com

HR® Pharmaceuticals, Inc. is a Delaware registered corporation headquartered in York, Pennsylvania.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

NO SINGLE MANUFACTURER CAN MEET CORONAVIRUS VACCINE GLOBAL DEMAND, SAYS MODERNA CEO

Cnbc | May 13, 2020

news image

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand. Regeneron CEO Leonard Schleifer, whose company is devel...

Read More

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

news image

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

news image

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More

Business Insights, PHARMA TECH

CERTARA ACQUIRES AI COMPANY VYASA TO BOOST SCIENTIFIC INNOVATION

Certara | January 05, 2023

news image

Certara, Inc. announced the acquisition of Vyasa Analytics, LLC, which offers scalable deep-learning software that enables life sciences enterprises to make predictions and answer complicated queries across structured and unstructured bio-medical data. The acquisition will improve Certara's software by giving its end-to-end platform cutting-edge artificial intelligence (AI) features. Certara said it was excited to announce that it had bought Vyasa, a cutting-edge company that ...

Read More
news image

NO SINGLE MANUFACTURER CAN MEET CORONAVIRUS VACCINE GLOBAL DEMAND, SAYS MODERNA CEO

Cnbc | May 13, 2020

Moderna CEO Stephane Bancel said Tuesday that he hopes many coronavirus vaccines from multiple manufacturers will be approved to enter the market, because no single manufacturer can meet global demand. Regeneron CEO Leonard Schleifer, whose company is devel...

Read More
news image

Business Insights

ATHIRA PHARMA ANNOUNCES TOPLINE RESULTS FROM ACT-AD PHASE 2 PROOF OF CONCEPT STUDY OF FOSGONIMETON IN MILD-TO-MODERATE ALZHEIMER’S DISEASE

Athira Pharma, Inc. | June 27, 2022

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain heal...

Read More
news image

Pharma Tech

INNATE PHARMA TO PRESENT LACUTAMAB PTCL PHASE 1B DESIGN AND ANKET™ PLATFORM AT ESMO 2022

Innate Pharma | September 06, 2022

Innate Pharma SA announced that the following presentations will be presented at the ESMO Annual Meeting 2022 taking place from 9 to 13 September 2022, in Paris, France. About Lacutamab Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma an orphan disease, and peripheral T cell lymphoma. Rare cutaneous lymphomas of T lymphocytes has a poor prognos...

Read More
news image

Business Insights, PHARMA TECH

CERTARA ACQUIRES AI COMPANY VYASA TO BOOST SCIENTIFIC INNOVATION

Certara | January 05, 2023

Certara, Inc. announced the acquisition of Vyasa Analytics, LLC, which offers scalable deep-learning software that enables life sciences enterprises to make predictions and answer complicated queries across structured and unstructured bio-medical data. The acquisition will improve Certara's software by giving its end-to-end platform cutting-edge artificial intelligence (AI) features. Certara said it was excited to announce that it had bought Vyasa, a cutting-edge company that ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us